Dementia is progressive decline in memory, reasoning, and daily function, most commonly caused by Alzheimer's disease, followed by vascular dementia, dementia with Lewy bodies, and frontotemporal dementia. It is currently estimated to affect 982,000 people in the UK, projected to rise to 1.4 million by 2040, and is the UK's leading cause of death.
Age is the strongest risk factor, but an estimated 45% of dementia cases are linked to modifiable factors across the life course (2024 Lancet Commission): hearing loss, high LDL cholesterol, depression, physical inactivity, diabetes, smoking, hypertension, obesity, excessive alcohol, fewer years of education, social isolation, air pollution, vision loss, and traumatic brain injury.
Elevated homocysteine, driven by low-normal vitamin B6, B12, and folate status, is independently linked to accelerated brain atrophy in older adults with mild cognitive impairment, and declining omega-3 status compounds this risk.
We build a personalised brain-health risk-reduction plan around each client's specific modifiable factors, identified through intake and diagnostics; cardiometabolic correction (blood pressure, LDL-C, glycaemic control), structured aerobic and resistance exercise, hearing assessment and correction, sleep and mood support, and social and cognitive engagement. Where testing shows elevated homocysteine alongside low-normal B vitamin status, we use targeted supplementation — folic acid, vitamin B12, and vitamin B6 to lower homocysteine, alongside omega-3 (EPA/DHA) correction where a client's Omega-3 Index is low. This work sits within our existing cardiometabolic and longevity protocols rather than as a stand-alone track, reflecting the multidomain nature of the evidence base.
A structured plan addressing the modifiable share of dementia risk through cardiometabolic correction, movement, sleep, hearing, and targeted supplementation where testing indicates a deficiency, tracked through repeat biomarkers across the programme. AdeaHealth does not diagnose, treat, or offer drug therapy for Alzheimer's disease; this is a risk-reduction and early-detection service only.
Clinical note: AdeaHealth does not offer, prescribe, or provide access to anti-amyloid antibody therapies (lecanemab, donanemab) or genetic dementia-risk testing (e.g. APOE4) as a routine service. Clients with a formal dementia diagnosis, cognitive impairment, or a family history requiring genetic counselling are referred to their GP, a memory clinic, or a specialist neurologist/geriatric psychiatrist.
Metabolic
Metabolic
Metabolic
Metabolic
Mental Health
Mental Health
Digestive
Hormonal
Energy
Recovery
Hormonal
Hormonal
Hormonal
Immune
Hormonal
Immune